These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
246 related items for PubMed ID: 21652078
1. Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. Ditta LC, Shildkrot Y, Wilson MW. Ophthalmology; 2011 Sep; 118(9):1754-9. PubMed ID: 21652078 [Abstract] [Full Text] [Related]
2. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. Demirci H, McCormick SA, Finger PT. Arch Ophthalmol; 2000 Jul; 118(7):885-91. PubMed ID: 10900099 [Abstract] [Full Text] [Related]
3. Limbal stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia. Lichtinger A, Pe'er J, Frucht-Pery J, Solomon A. Ophthalmology; 2010 Mar; 117(3):431-7. PubMed ID: 20060167 [Abstract] [Full Text] [Related]
4. [Treatment of 9 squamous epithelial carcinoma in situ lesions of the conjunctiva (CIN) with mitomycin C eyedrops in cytological and DNA image cytometric control]. Cartsburg O, Kersten A, Sundmacher R, Nadjari B, Pomjanski N, Böcking A. Klin Monbl Augenheilkd; 2001 Jun; 218(6):429-34. PubMed ID: 11488009 [Abstract] [Full Text] [Related]
5. Treatment of ocular surface squamous neoplasia with Mitomycin C. Gupta A, Muecke J. Br J Ophthalmol; 2010 May; 94(5):555-8. PubMed ID: 20447963 [Abstract] [Full Text] [Related]
6. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience. Kurli M, Finger PT. Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1108-14. PubMed ID: 15940485 [Abstract] [Full Text] [Related]
7. Topical mitomycin C for the treatment of conjunctival tumor. Ozcan AA, Sizmaz S, Yagmur M. Ophthalmologica; 2007 Nov; 221(1):14-7. PubMed ID: 17183195 [Abstract] [Full Text] [Related]
8. Postoperative topical mitomycin C in conjunctival squamous cell neoplasia. Akpek EK, Ertoy D, Kalayci D, Hasiripi H. Cornea; 1999 Jan; 18(1):59-62. PubMed ID: 9894938 [Abstract] [Full Text] [Related]
9. Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia. Dudney BW, Malecha MA. Am J Ophthalmol; 2004 May; 137(5):950-1. PubMed ID: 15126170 [Abstract] [Full Text] [Related]
15. Cytologic changes in the conjunctiva mimicking malignancy after topical mitomycin C chemotherapy. Salomão DR, Mathers WD, Sutphin JE, Cuevas K, Folberg R. Ophthalmology; 1999 Sep; 106(9):1756-60; discussion 1761. PubMed ID: 10485547 [Abstract] [Full Text] [Related]
16. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Shields CL. Trans Am Ophthalmol Soc; 2000 Sep; 98():471-92. PubMed ID: 11190037 [Abstract] [Full Text] [Related]
17. Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. Prabhasawat P, Tarinvorakup P, Tesavibul N, Uiprasertkul M, Kosrirukvongs P, Booranapong W, Srivannaboon S. Cornea; 2005 May; 24(4):443-8. PubMed ID: 15829803 [Abstract] [Full Text] [Related]
18. Epiphora as a side effect of topical mitomycin C. Kopp ED, Seregard S. Br J Ophthalmol; 2004 Nov; 88(11):1422-4. PubMed ID: 15489486 [Abstract] [Full Text] [Related]